Recap: CancerNetwork® Tweet Chat on Prostate Cancer

Article

In a mock tumor board on prostate cancer on Twitter, health care providers came together to discuss real patient cases and present various treatment options for review.

In a mock tumor board on prostate cancer organized by CancerNetwork® on Twitter, health care providers came together to discuss real patient cases and present various treatment options for review, with guest commentary on each case offered from experts in the field.

Led by Judd W. Moul, MD, FACS, a urologic oncologist at Duke Cancer Center and Duke Urology Clinic, the chat featured guest commentary from Daniel Spratt, MD, chief of the Genitourinary Radiotherapy Program, associate chair of Clinical Research, and the Laurie Snow Endowed Research Professor at the Rogel Cancer Center of the University of Michigan, Alicia K. Morgans, MD, MPH, associate professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine, and Stacy Loeb, MD, MSc, PhD (hon.), professor of Urology and Population Health at NYU Langone Health and the Manhattan Veterans Affairs.

In case you missed it, here is a recap of the questions presented and the answers selected by participants:

tweet chat question 1

tweet chat question 2

tweet chat question 3

tweet chat question 4

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content
Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.

FDA Accepts sNDA for Darolutamide/ADT in Hormone-Sensitive Prostate Cancer

Tim Cortese
November 21st 2024
Article

Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.

SBRT Emerges as Viable Treatment for Localized Prostate Cancer

Tim Cortese
November 12th 2024
Article

Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Judd W. Moul, MD;Kostantinos E. Morris, BS
May 30th 2022
Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.

Darolutamide/ADT Improves rPFS in Metastatic HSPC

Jonah Feldman
October 13th 2024
Article

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.

Apalutamide Significantly Improves OS Vs Enzalutamide in Metastatic CSPC

Roman Fabbricatore
October 11th 2024
Article

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.